Sadanowicz, Mara
https://orcid.org/0009-0005-0322-1110
Mayo Clinic
Karyopharm Therapeutics (United States)
Citations 1
Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.
Gounder, Mrinal M. , Somaiah, Neeta , Attia, Steven , Chawla, Sant P. , Villalobos, Víctor M. , Riedel, Richard F. , Wagner, Andrew J. , Mudenda, Boyd, Sadanowicz, Mara , Shah, Jatin J., Shacham, Sharon, Kauffman, Michael , Razak, Albiruni Ryan Abdul, Riedel, Richard F , Chmielowski, Bartosz , Burgess, Melissa , Schwartz, Gary K. , Mehren, Margaret von , Choy, Edwin , Verma, Shailendra , Li, Lingling
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11512-11512
